Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01025817 · ClinicalTrials.gov registry record · Phase 3
Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 613
- Enrollment target
NCT01025817 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 613 participants.
The verdict
NCT01025817, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 613 participants
- Enrollment target
Study Summary
The purpose of this phase 3b study is to compare the safety and efficacy of everolimus with low dose tacrolimus to mycophenolate mofetil with standard dose tacrolimus in kidney transplant recipients.
Interventions
- DRUG Everolimus and tacrolimus
- DRUG mycophenolate mofetil and tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 613 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01025817
The ClinicalTrials.gov registry entry for NCT01025817 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 613 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus and tacrolimus is the first listed.
NCT01025817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01025817 about?
NCT01025817 is a clinical study titled "Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients". The purpose of this phase 3b study is to compare the safety and efficacy of everolimus with low dose tacrolimus to mycophenolate mofetil with standard dose tacrolimus in kidney transplant recipients.
What is the current status of trial NCT01025817?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 613 participants. The study started on 2010-01. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01025817?
The interventions under investigation include: Everolimus and tacrolimus (DRUG), mycophenolate mofetil and tacrolimus (DRUG).
Who is sponsoring clinical trial NCT01025817?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.